A5066214064- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Peptidase Inhibition and Analysis
- Medical Imaging and Pathology Studies
- Cancer, Hypoxia, and Metabolism
- Atomic and Subatomic Physics Research
- Nanoparticle-Based Drug Delivery
- Venous Thromboembolism Diagnosis and Management
- Cancer, Lipids, and Metabolism
- Immune Cell Function and Interaction
- Ultrasound in Clinical Applications
- Radiation Dose and Imaging
- MRI in cancer diagnosis
- Cardiac Imaging and Diagnostics
- Receptor Mechanisms and Signaling
- Lanthanide and Transition Metal Complexes
- Monoclonal and Polyclonal Antibodies Research
- Polyomavirus and related diseases
- Reproductive System and Pregnancy
St Vincent's Hospital Sydney
2020-2023
Peter MacCallum Cancer Centre
2013-2022
Deakin University
2018-2020
The University of Melbourne
2011-2017
Monash University
2015
Creative Commons
2015
Royal Children's Hospital
2015
Monash Health
2015
Centre hospitalier universitaire de Québec
2011
Université Laval
2011
<sup>177</sup>Lu-prostate-specific membrane antigen (PSMA)–617 enables targeted delivery of β-particle radiation to prostate cancer. We determined its dosimetry and relationships pretherapeutic imaging outcomes. <b>Methods:</b> Thirty patients with cancer receiving <sup>177</sup>Lu-PSMA-617 within a prospective clinical trial (ACTRN12615000912583) were studied. Screening <sup>68</sup>Ga-PSMA-11 PET/CT demonstrated high PSMA expression in all patients. After therapy, underwent quantitative...
Abstract Introduction: Ga‐68 DOTATATE (Ga‐octreotate, GaTate) positron emission tomography (PET)/CT has multiple advantages compared with conventional and In‐111 octreotide imaging for neuroendocrine tumours other somatostatin‐receptor expressing tumours. This study assesses the management impact of incremental diagnostic information obtained from this technique staging. Methods: Fifty‐nine GaTate PET/CT studies were performed over an 18‐month period (52 proven or suspected...
<sup>177</sup>Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity low toxicity in prospective phase II trial involving 30 men metastatic castration-resistant now report their longer-term outcomes, including 20-patient extension cohort and outcomes subsequent systemic treatments after completion therapy. <b>Methods:</b> Fifty patients PSMA-avid cancer...
Purpose: To investigate the dosimetric accuracy of sliding window gated IMRT compared with static treatment, using varying dose rates.Materials and methods: This study measured changes in output diode array response changing rate, verified precision motion table, distribution film diodes at two depths rate.During 4DCT (4 Dimensional Computed Tomography), patient's respiratory signals target were recorded imported to XY4D simulation table SUN NUCLEAR Corporation simulate respiration tumour...
Pediatric patients with refractory neuroblastoma have limited therapeutic options. Neuroblastoma may express somatostatin receptors (SSTRs) allowing imaging 68Ga-DOTA-Octreotate (GaTATE) positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT). We reviewed our experience this theranostic combination.GaTATE studies (8 patients; 2 to 9 years old) were compared 123I-MIBG or posttreatment 131I-MIBG studies. Immunohistochemistry (IHC) for SSTR...
Abstract Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though regression occurs in only a minority of patients. Therefore, novel PRRT regimens improved therapeutic activity are needed. Radiation induced DNA damage repair attractive target to increase efficacy and consequently, we have characterised panel preclinical models their SSTR2 expression, vivo growth properties...
177LuPSMA is an effective treatment in metastatic castrate-resistant prostate cancer with trials adopting a standardised dose interval. Adjusting intervals utilising early response biomarkers may improve patient outcomes.This study evaluated progression-free survival (PFS) and overall (OS) based on interval adjustment 24-h SPECT/CT (177Lu-SPECT) prostate-specific antigen (PSA) response.Retrospective analysis of clinical 177Lu-PSMA-I&T programme.In all, 125 men were treated 6-weekly...
Ventilation-perfusion (V/Q) scintigraphy is established for regional assessment of lung function in a variety diseases, including pulmonary embolism (PE). PET/CT may further improve the accuracy and utility V/Q imaging because its superior technical characteristics. This pilot study assessed feasibility performing compared diagnostic with conventional patients clinical suspicion PE.Ten undergoing were prospectively recruited. was performed after inhalation (68)Ga-carbon nanoparticles...
To review the response and outcomes of (177)Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels somatostatin receptors uncontrolled symptoms or disease progression.A total 68 (39 men; 17 - 76 years age) who had completed an induction course at least three cycles LuTate PRCRT between January 2006 June 2010 were reviewed. Ten treated for 58 progression despite conventional treatment. The majority four (median treatment...
68Ga-labeled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED)-PSMA-11, are promising small molecules for targeting prostate cancer. A new radiopharmaceutical, tris(hydroxypyridinone) (THP)-PSMA, has a simplified design single-step kit-based radiolabeling. It features THP ligand, which forms complexes with 68Ga3+ rapidly at low concentration, room temperature, and over wide pH range, enabling...
<sup>177</sup>Lu-PSMA-617 is an effective and novel treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates therefore efficacy may be improved using predictive tools. This study investigated the value of serial SPECT/CT (<sup>177</sup>Lu SPECT) imaging monitoring response. <b>Methods:</b> Fifty-six men with progressive mCRPC previously treated chemotherapy androgen signaling inhibitor were enrolled into LuPIN trial received up 6 doses a...
Despite substantial improvements in early survival after lung transplantation, refractory acute rejection (RAR) and bronchiolitis obliterans syndrome (BOS) remain major contributors to transplant-related morbidity mortality. We have utilized alemtuzumab, a humanized anti-CD52 antibody which results potent lymphocyte depletion, consecutive patients with RAR (n = 12) or BOS 10). All failed conventional treatment methylprednisolone antithymocyte globulin received strict infection prophylaxis....
Abstract Introduction For many cancers, tumour hypoxia is an adverse prognostic factor, and increases chemoradiation resistance; its importance in non‐small cell lung cancer ( NSCLC ) unproven. This study evaluated tumoural using fluoroazomycin arabinoside 18 F ‐ FAZA positron emission tomography PET scans among patients with locoregionally advanced treated definitive chemoradiation. Methods Patients stage IIIA‐IIIB underwent F‐2‐deoxyglucose FDG )‐ within 4 weeks of commencing 8 following...
Development of magnetic resonance imaging (MRI) contrast agents that can be readily applied for biological tissues under clinical settings is a challenging task. This predominantly due to the expectation an ideal MR agent being able synthesized in large quantities, possessing longer shelf life, reasonable biocompatibility, tolerance against its aggregation fluids, and high relaxivity, resulting better during imaging. Although repertoire reports address various aforementioned issues,...
<b>Background:</b><sup>177</sup>Lutetium PSMA-617 (Lu-PSMA-617) is an effective therapy for metastatic castrate-resistant prostate cancer (mCRPC). However, treatment resistance occurs frequently and combination therapies may improve outcomes. We report the final safety efficacy results of a phase I/II study combining Lu-PSMA-617 with idronoxil (NOX66), radiosensitiser, examined potential clinical, blood-based imaging biomarkers. <b>Methods:</b> 56 men progressive mCRPC previously treated...